Last 12 months
Inside the activity.
0 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2023 Filed May 5, 2023 00:28 UTC |
Khosla RachnaSVP, Business Development
|
Tax withholdingCommon Stock | 57 | $235.97 | $13,450.29 |
DisclosureSEC source: 0001127602-23-014609 · form4.xml · nonDerivative · entry 2 Khosla Rachna · CIK 0001881332 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,620 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 201 RSUs which will vest in installments of 99 on 5/5/2023 and 102 on 5/5/2024; 252 RSUs which will vest in installments of 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; 468 RSUs which will vest on 11/5/2023; 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026; and 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and one installment of 202 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 137 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2023 Filed May 5, 2023 00:31 UTC |
Miller DerekSVP, Human Resources
|
Tax withholdingCommon Stock | 57 | $235.97 | $13,450.29 |
DisclosureSEC source: 0001127602-23-014611 · form4.xml · nonDerivative · entry 2 Miller Derek · CIK 0001917312 · SVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,604 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 114 RSUs which will vest in installments of 56 on 5/5/2023 and 58 on 5/5/2024; 974 RSUs which will vest in installments of 479 on 11/2/2023 and 495 on 11/2/2024; 201 RSUs which will vest in installments of 99 on 4/30/2024 and 102 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; 433 RSUs which will vest in installments of 142 on 5/2/2024, 143 on 5/2/2025, and 148 on 5/5/2026.; and 1,101 RSUs which will vest in two installments of 363 on 5/2/2025 and 5/2/2026, and 375 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 81 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2023 Filed May 5, 2023 00:32 UTC |
REESE DAVID MEVP, Research and Development
|
Tax withholdingCommon Stock | 819 | $235.97 | $193,259.43 |
DisclosureSEC source: 0001127602-23-014612 · form4.xml · nonDerivative · entry 2 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,708 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 2,325 RSUs which will vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 2,685 RSUs which will vest in installments of 1,322 on 4/30/2024 and 1,363 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 528 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2023 Filed May 5, 2023 00:33 UTC |
Santos EstebanEVP, Operations
|
Tax withholdingCommon Stock | 716 | $235.97 | $168,954.52 |
DisclosureSEC source: 0001127602-23-014613 · form4.xml · nonDerivative · entry 2 Santos Esteban · CIK 0001677950 · EVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,161 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 2,268 RSUs which will vest in installments of 1,117 on 5/5/2023 and 1,151 on 5/5/2024; 2,656 RSUs which will vest in installments of 1,308 on 4/30/2024 and 1,348 on 4/30/2025; 3,637 RSUs which will vest in two installments of 1,200 on 5/2/2024 and on 5/2/2025, and one installment of 1,237 on 5/2/2026; and 3,559 RSUs which vest in two installments of 1,174 on 5/2/2025 and 5/2/2026, and 1,211 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 512 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2023 Filed May 5, 2023 00:35 UTC |
Grygiel Nancy A.SVP & CCO
|
Tax withholdingCommon Stock | 62 | $235.97 | $14,630.14 |
DisclosureSEC source: 0001127602-23-014614 · form4.xml · nonDerivative · entry 2 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,278 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 284 RSUs which will vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 392 RSUs which will vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026; and 635 RSUs which will vest in installments of 209 on 5/2/2025, 210 on 5/2/2026 and 216 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 584 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2023 Filed May 4, 2023 00:31 UTC |
Drake Michael VDirector
|
GrantCommon Stock | 137.7294 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014372 · form4.xml · nonDerivative · entry 1 Drake Michael V · CIK 0001938942 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 960.7339 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSU's may be deferred by the director, in which case payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 18 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2023 Filed May 4, 2023 00:33 UTC |
HOLLEY CHARLES MDirector
|
GrantCommon Stock | 169.5131 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014373 · form4.xml · nonDerivative · entry 1 HOLLEY CHARLES M · CIK 0001216478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,039.6716 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 627 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2023 Filed May 4, 2023 00:34 UTC |
ISHRAK OMARDirector
|
GrantCommon Stock | 137.7294 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014374 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,461.635 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 40 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:23 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
GrantNqso (Right to Buy) · Derivative | 114,040 | $0.00 Strike: $235.97 | $0.00 |
DisclosureSEC source: 0001127602-23-014605 · form4.xml · derivative · entry 3 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,040 Underlying: Common Stock · 114,040 shares Expires 2033-05-02 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:23 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
GrantCommon Stock | 13,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014605 · form4.xml · nonDerivative · entry 1 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 646,680 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:24 UTC |
Griffith Peter H.EVP & CFO
|
GrantNqso (Right to Buy) · Derivative | 32,250 | $0.00 Strike: $235.97 | $0.00 |
DisclosureSEC source: 0001127602-23-014606 · form4.xml · derivative · entry 2 Griffith Peter H. · CIK 0001798821 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,250 Underlying: Common Stock · 32,250 shares Expires 2033-05-02 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:24 UTC |
Griffith Peter H.EVP & CFO
|
GrantCommon Stock | 3,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014606 · form4.xml · nonDerivative · entry 1 Griffith Peter H. · CIK 0001798821 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,598 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 6,240 RSUs which will vest on 11/1/2023; 2,268 RSUs which will vest in installments of 1,117 on 5/5/2023 and 1,151 on 5/5/2024; 2,237 RSUs which will vest in installments of 1,102 on 4/30/2024 and 1,135 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026 and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,188 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:25 UTC |
Graham Jonathan PEVP, Gen. Counsel & Secy.
|
GrantNqso (Right to Buy) · Derivative | 28,666 | $0.00 Strike: $235.97 | $0.00 |
DisclosureSEC source: 0001127602-23-014607 · form4.xml · derivative · entry 3 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,666 Underlying: Common Stock · 28,666 shares Expires 2033-05-02 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:25 UTC |
Graham Jonathan PEVP, Gen. Counsel & Secy.
|
GrantCommon Stock | 3,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014607 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,767 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:27 UTC |
Gordon MurdoEVP, Global Commercial Ops
|
GrantNqso (Right to Buy) · Derivative | 35,833 | $0.00 Strike: $235.97 | $0.00 |
DisclosureSEC source: 0001127602-23-014608 · form4.xml · derivative · entry 3 Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,833 Underlying: Common Stock · 35,833 shares Expires 2033-05-02 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:27 UTC |
Gordon MurdoEVP, Global Commercial Ops
|
GrantCommon Stock | 4,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014608 · form4.xml · nonDerivative · entry 1 Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,348 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:28 UTC |
Khosla RachnaSVP, Business Development
|
GrantNqso (Right to Buy) · Derivative | 5,016 | $0.00 Strike: $235.97 | $0.00 |
DisclosureSEC source: 0001127602-23-014609 · form4.xml · derivative · entry 3 Khosla Rachna · CIK 0001881332 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,016 Underlying: Common Stock · 5,016 shares Expires 2033-05-02 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:28 UTC |
Khosla RachnaSVP, Business Development
|
GrantCommon Stock | 593 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014609 · form4.xml · nonDerivative · entry 1 Khosla Rachna · CIK 0001881332 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,677 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:30 UTC |
Louie Linda H.VP, Finance & CAO
|
GrantNqso (Right to Buy) · Derivative | 3,583 | $0.00 Strike: $235.97 | $0.00 |
DisclosureSEC source: 0001127602-23-014610 · form4.xml · derivative · entry 3 Louie Linda H. · CIK 0001818953 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,583 Underlying: Common Stock · 3,583 shares Expires 2033-05-02 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:30 UTC |
Louie Linda H.VP, Finance & CAO
|
Tax withholdingCommon Stock | 20 | $235.97 | $4,719.40 |
DisclosureSEC source: 0001127602-23-014610 · form4.xml · nonDerivative · entry 2 Louie Linda H. · CIK 0001818953 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,982 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 114 RSUs which will vest in installments of 56 on 5/5/2023 and 58 on 5/5/2024; 974 RSUs which will vest in installments of 479 on 11/2/2023 and 495 on 11/2/2024; 201 RSUs which will vest in installments of 99 on 4/30/2024 and 102 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; 433 RSUs which will vest in installments of 142 on 5/2/2024, 143 on 5/2/2025, and 148 on 5/5/2026; and 423 RSUs which will vest in installments of 139 on 5/2/2025, 140 on 5/2/2026 and 144 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 127 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:30 UTC |
Louie Linda H.VP, Finance & CAO
|
GrantCommon Stock | 423 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014610 · form4.xml · nonDerivative · entry 1 Louie Linda H. · CIK 0001818953 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,002 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:31 UTC |
Miller DerekSVP, Human Resources
|
GrantNqso (Right to Buy) · Derivative | 9,316 | $0.00 Strike: $235.97 | $0.00 |
DisclosureSEC source: 0001127602-23-014611 · form4.xml · derivative · entry 3 Miller Derek · CIK 0001917312 · SVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,316 Underlying: Common Stock · 9,316 shares Expires 2033-05-02 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:31 UTC |
Miller DerekSVP, Human Resources
|
GrantCommon Stock | 1,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014611 · form4.xml · nonDerivative · entry 1 Miller Derek · CIK 0001917312 · SVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,661 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:32 UTC |
REESE DAVID MEVP, Research and Development
|
GrantNqso (Right to Buy) · Derivative | 32,250 | $0.00 Strike: $235.97 | $0.00 |
DisclosureSEC source: 0001127602-23-014612 · form4.xml · derivative · entry 3 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,250 Underlying: Common Stock · 32,250 shares Expires 2033-05-02 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:32 UTC |
REESE DAVID MEVP, Research and Development
|
GrantCommon Stock | 3,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014612 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,527 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:33 UTC |
Santos EstebanEVP, Operations
|
GrantNqso (Right to Buy) · Derivative | 30,100 | $0.00 Strike: $235.97 | $0.00 |
DisclosureSEC source: 0001127602-23-014613 · form4.xml · derivative · entry 4 Santos Esteban · CIK 0001677950 · EVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,100 Underlying: Common Stock · 30,100 shares Expires 2033-05-02 F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:33 UTC |
Santos EstebanEVP, Operations
|
GrantCommon Stock | 3,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014613 · form4.xml · nonDerivative · entry 1 Santos Esteban · CIK 0001677950 · EVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,877 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:35 UTC |
Grygiel Nancy A.SVP & CCO
|
GrantNqso (Right to Buy) · Derivative | 5,375 | $0.00 Strike: $235.97 | $0.00 |
DisclosureSEC source: 0001127602-23-014614 · form4.xml · derivative · entry 4 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,375 Underlying: Common Stock · 5,375 shares Expires 2033-05-02 F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:35 UTC |
Grygiel Nancy A.SVP & CCO
|
GrantCommon Stock | 635 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014614 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,340 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. Read SEC document |
| April 30, 2023 Filed May 3, 2023 00:15 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 2,208 | $239.74 | $529,345.92 |
DisclosureSEC source: 0001127602-23-014149 · form4.xml · nonDerivative · entry 1 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 633,194 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,369 RSUs which will vest on 5/3/2023; 8,164 RSUs which vest in installments of 4,021 on 5/5/2023 and 4,143 on 5/5/2024; 8.898 RSUs which vest in installments of 4,382 on 4/30/2024 and 4,516 on 4/30/2025; and 13,781 RSUs which will vest in installments of 4,547 on 5/2/2024, 4,548 on 5/2/2025, and 4,686 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 2,508 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 30, 2023 Filed May 3, 2023 00:16 UTC |
Gordon MurdoEVP, Global Commercial Ops
|
Tax withholdingCommon Stock | 728 | $239.74 | $174,530.72 |
DisclosureSEC source: 0001127602-23-014150 · form4.xml · nonDerivative · entry 1 Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,111 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,534 RSUs which vest in one installment on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 2,796 RSUs which vest in installments of 1,377 on 4/30/2024 and 1,419 on 4/30/2025; and 4,330 vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 746 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 30, 2023 Filed May 3, 2023 00:19 UTC |
Graham Jonathan PEVP, Gen. Counsel & Secy.
|
Tax withholdingCommon Stock | 664 | $239.74 | $159,187.36 |
DisclosureSEC source: 0001127602-23-014151 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,377 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,074 RSUs which will vest on 5/3/2023; 3,120 RSUs which will vest on 11/1/2023; 2,211 RSUs which will vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 2,544 RSUs which will vest in installments of 1,253 on 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 975 DEs granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 30, 2023 Filed May 3, 2023 00:21 UTC |
Griffith Peter H.EVP & CFO
|
Tax withholdingCommon Stock | 583 | $239.74 | $139,768.42 |
DisclosureSEC source: 0001127602-23-014152 · form4.xml · nonDerivative · entry 1 Griffith Peter H. · CIK 0001798821 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,784 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,240 RSUs which will vest on 11/1/2023; 2,268 RSUs which will vest in installments of 1,117 on 5/5/2023 and 1,151 on 5/5/2024; 2,237 RSUs which will vest in installments of 1,102 on 4/30/2024 and 1,135 on 4/30/2025; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,188 DEs granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| April 30, 2023 Filed May 3, 2023 00:23 UTC |
Grygiel Nancy A.SVP & CCO
|
Tax withholdingCommon Stock | 73 | $239.74 | $17,501.02 |
DisclosureSEC source: 0001127602-23-014153 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,705 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plan: 154 RSUs which vest in one installment on 5/3/2023; 284 RSUs which vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 392 RSUs which vest in installments of 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 604 DEs granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 30, 2023 Filed May 3, 2023 00:24 UTC |
Khosla RachnaSVP, Business Development
|
Tax withholdingCommon Stock | 47 | $239.74 | $11,267.78 |
DisclosureSEC source: 0001127602-23-014154 · form4.xml · nonDerivative · entry 1 Khosla Rachna · CIK 0001881332 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,084 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plan: 142 RSUs which will vest on 5/3/2023; 201 RSUs which will vest in installments of 99 on 5/5/2023 and 102 on 5/5/2024; 252 RSUs which will vest in installments of 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; 468 RSUs which will vest on 11/5/2023; and 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 156 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 30, 2023 Filed May 3, 2023 00:24 UTC |
Louie Linda H.VP, Finance & CAO
|
Tax withholdingCommon Stock | 27 | $239.74 | $6,472.98 |
DisclosureSEC source: 0001127602-23-014155 · form4.xml · nonDerivative · entry 1 Louie Linda H. · CIK 0001818953 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,579 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 67 RSUs which will vest on 5/3/2023; 114 RSUs which will vest in installments of 56 on 5/5/2023 and 58 on 5/5/2024; 974 RSUs which will vest in one installment of 479 on 11/2/2023 and one installment of 495 on 11/2/2024; 201 RSUs which will vest in one installment of 99 on 4/30/2024 and one installment of 102 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; and 433 RSUs which will vest in installments of 142 on 5/2/2024, 143 on 5/2/2025, and 148 on 5/5/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 136 DEs granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 30, 2023 Filed May 3, 2023 00:26 UTC |
Miller DerekSVP, Human Resources
|
Tax withholdingCommon Stock | 50 | $239.74 | $11,987.00 |
DisclosureSEC source: 0001127602-23-014156 · form4.xml · nonDerivative · entry 1 Miller Derek · CIK 0001917312 · SVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,560 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Equity Incentive Plan:144 RSUs which vest on 5/3/2023; 269 RSUs which will vest in installments of 132 on 5/5/2023 and 137 on 5/5/2024; 263 RSUs which will vest in one installment of 129 on 4/30/2024 and one installment of 134 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; and 866 RSUs which will vest in installments of 285 on 5/2/2024, 286 on 5/2/2025, and 295 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 100 DEs granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 30, 2023 Filed May 3, 2023 00:28 UTC |
REESE DAVID MEVP, Research and Development
|
Tax withholdingCommon Stock | 666 | $239.74 | $159,666.84 |
DisclosureSEC source: 0001127602-23-014157 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,713 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,534 RSUs which will vest on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 2,685 RSUs which vest in installments of 1,322 on 4/30/2024 and 1,363 on 4/30/2025; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 725 DEs granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 30, 2023 Filed May 3, 2023 00:29 UTC |
Santos EstebanEVP, Operations
|
Tax withholdingCommon Stock | 660 | $239.74 | $158,228.40 |
DisclosureSEC source: 0001127602-23-014158 · form4.xml · nonDerivative · entry 2 Santos Esteban · CIK 0001677950 · EVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,318 F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,342 RSUs which vest on 5/3/2023; 2,268 RSUs which vest in installments of 1,117 on 5/5/2023 and 1,151 on 5/5/2024; 2,656 RSUs which vest in installments of 1,308 on 4/30/2024 and 1,348 on 4/30/2025; and 3,637 RSUs which will vest in two installments of 1,200 on 5/2/2024 and on 5/2/2025, and one installment of 1,237 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 684 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 22:42 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 13,971 | $234.57 | $3,277,177.47 |
DisclosureSEC source: 0001127602-23-010906 · form4.xml · nonDerivative · entry 1 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 635,402 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,369 RSUs which will vest on 5/3/2023; 8,164 RSUs which vest in installments of 4,021 on 5/5/2023 and 4,143 on 5/5/2024; 13,280 RSUs which vest in two installments of 4,382 on 4/30/2023 and 4/30/2024 and one installment of 4,516 on 4/30/2025; and 13,781 RSUs which will vest in installments of 4,547 on 5/2/2024, 4,548 on 5/2/2025, and 4,686 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 2,796 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 23:05 UTC |
Gordon MurdoEVP, Global Commercial Ops
|
Tax withholdingCommon Stock | 3,978 | $234.57 | $933,119.46 |
DisclosureSEC source: 0001127602-23-010914 · form4.xml · nonDerivative · entry 1 Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,839 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,534 RSUs which vest in one installment on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025; and 4,330 vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 836 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 23:07 UTC |
Graham Jonathan PEVP, Gen. Counsel & Secy.
|
Tax withholdingCommon Stock | 3,785 | $234.57 | $887,847.45 |
DisclosureSEC source: 0001127602-23-010915 · form4.xml · nonDerivative · entry 1 Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,041 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,074 RSUs which will vest on 5/3/2023; 3,120 RSUs which will vest on 11/1/2023; 2,211 RSUs which will vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 3,797 RSUs which will vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,057 DEs granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 23:08 UTC |
Griffith Peter H.EVP & CFO
|
Tax withholdingCommon Stock | 3,403 | $234.57 | $798,241.71 |
DisclosureSEC source: 0001127602-23-010916 · form4.xml · nonDerivative · entry 1 Griffith Peter H. · CIK 0001798821 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,367 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 6,240 RSUs which will vest on 11/1/2023; 2,268 RSUs which will vest in installments of 1,117 on 5/5/2023 and 1,151 on 5/5/2024; 3,338 RSUs which will vest in installments of 1,101 on 4/30/2023, 1,102 on 4/30/2024 and 1,135 on 4/30/202; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,260 DEs granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 23:09 UTC |
Grygiel Nancy A.SVP & CCO
|
Tax withholdingCommon Stock | 339 | $234.57 | $79,519.23 |
DisclosureSEC source: 0001127602-23-010917 · form4.xml · nonDerivative · entry 1 Grygiel Nancy A. · CIK 0001816414 · SVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,778 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plan: 154 RSUs which will vest on 5/3/2023; 284 RSUs which will vest in installments of 140 on 5/5/2023 and 144 on 5/5/2024; 5,477 RSUs which will vest in installments of 2,697 on 7/31/2023 and 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; 468 RSUs which will vest on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 616 DEs granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 23:10 UTC |
Khosla RachnaSVP, Business Development
|
Tax withholdingCommon Stock | 241 | $234.57 | $56,531.37 |
DisclosureSEC source: 0001127602-23-010918 · form4.xml · nonDerivative · entry 1 Khosla Rachna · CIK 0001881332 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,103 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plan: 142 RSUs which vest in one installment on 5/3/2023; 201 RSUs which will vest in installments of 99 on 5/5/2023 and 102 on 5/5/2024; 375 RSUs which will vest in installments of 123 on 4/30/2023, 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023; and 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 135 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 23:12 UTC |
Louie Linda H.VP, Finance & CAO
|
Tax withholdingCommon Stock | 96 | $234.57 | $22,518.72 |
DisclosureSEC source: 0001127602-23-010919 · form4.xml · nonDerivative · entry 1 Louie Linda H. · CIK 0001818953 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,606 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 67 RSUs which will vest on 5/3/2023; 114 RSUs which will vest in installments of 56 on 5/5/2023 and 58 on 5/5/2024; 974 RSUs which will vest in one installment of 479 on 11/2/2023 and one installment of 495 on 11/2/2024; 300 RSUs which will vest in two installments of 99 on 4/30/2023 and 4/30/2024 and one installment of 102 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; and 433 RSUs which will vest in installments of 142 on 5/2/2024, 143 on 5/2/2025, and 148 on 5/5/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 142 DEs granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 23:13 UTC |
Miller DerekSVP, Human Resources
|
Tax withholdingCommon Stock | 322 | $234.57 | $75,531.54 |
DisclosureSEC source: 0001127602-23-010921 · form4.xml · nonDerivative · entry 1 Miller Derek · CIK 0001917312 · SVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,610 F1 · balance_after: These shares include the following RSUs granted under the Amgen Inc. 2009 Equity Incentive Plan: 144 RSUs which vest on 5/3/2023; 269 RSUs which will vest in installments of 132 on 5/5/2023 and 137 on 5/5/2024; 392 RSUs which will vest in two installments of 129 on 4/30/2023 and 4/30/2024 and one installment of 134 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; and 866 RSUs which will vest in installments of 285 on 5/2/2024, 286 on 5/2/2025, and 295 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 108 DEs granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 23:14 UTC |
REESE DAVID MEVP, Research and Development
|
Tax withholdingCommon Stock | 3,978 | $234.57 | $933,119.46 |
DisclosureSEC source: 0001127602-23-010922 · form4.xml · nonDerivative · entry 1 REESE DAVID M · CIK 0001748434 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,379 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,534 RSUs which will vest on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,006 RSUs which vest in installments of 1,321 on 4/30/2023, 1,322 on 4/30/2024 and 1,363 on 4/30/2025; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 811 DEs granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 23:16 UTC |
Santos EstebanEVP, Operations
|
Tax withholdingCommon Stock | 3,881 | $234.57 | $910,366.17 |
DisclosureSEC source: 0001127602-23-010925 · form4.xml · nonDerivative · entry 1 Santos Esteban · CIK 0001677950 · EVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,978 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,342 RSUs which vest on 5/3/2023; 2,268 RSUs which vest in installments of 1,117 on 5/5/2023 and 1,151 on 5/5/2024; 3,964 RSUs which vest in two installments of 1,308 on 4/30/2023 and 4/30/2024 and one installment of 1,348 on 4/30/2025; and 3,637 RSUs which will vest in two installments of 1,200 on 5/2/2024 and on 5/2/2025, and one installment of 1,237 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 769 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 00:03 UTC |
Santos EstebanEVP, Operations
|
GrantCommon Stock | 7,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-009493 · form4.xml · nonDerivative · entry 2 Santos Esteban · CIK 0001677950 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,676 F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,342 RSUs which vest on 5/3/2023; 2,268 RSUs which vest in installments of 1,117 on 5/5/2023 and 1,151 on 5/5/2024; 3,964 RSUs which vest in two installments of 1,308 on 4/30/2023 and 4/30/2024 and one installment of 1,348 on 4/30/2025; and 3,637 RSUs which will vest in two installments of 1,200 on 5/2/2024 and on 5/2/2025, and one installment of 1,237 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 658 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.